Treatment of acute agitation in psychotic disorders

Transcription

1 Neuroendocrinology Letters No.4 August Vol.26, 2005 Copyright 2005 Neuroendocrinology Letters ISSN X Treatment of acute agitation in psychotic disorders Pavel Mohr 1, Ján Pečeňák 2, Jaromír Švestka 3, Dave Swingler 4 & Tamás Treuer 5 1 Prague Psychiatric Center, Czech Republic 2 Department of Psychiatry, University Hospital Bratislava, Slovakia 3 Psychiatric Clinic, Medical Faculty, Masaryk University Brno, Czech Republic 4 Fort England Hospital & Rhodes University Grahamstown, South Africa 5 Eli Lilly, Area Medical Center Vienna, Austria Correspondence to: Ass. Prof. Dr. Pavel Mohr, PhD Prague Psychiatric Center Ustavni 91, Praha 8, Czech Republic TEL: , FAX: Submitted: July 15, 2005 Accepted: July 29, 2005 Key words: agitation; schizophrenia; second generation antipsychotics; olanzapine; ziprasidone Neuroendocrinol Lett 2005; 26(4): PMID: NEL260405R03 Neuroendocrinology Letters Abstract Several psychotic disorders, including schizophrenia, may be associated with symptoms of acute agitation and aggression. While drug treatment of agitation is often essential, non-pharmacological interventions, both environmental and behavioral, also play important roles in the complex management of agitated patients. The most extensively used psychotropic drugs are parenteral formulas of conventional antipsychotics and benzodiazepines. Recently, injection forms of two second generation antipsychotics, olanzapine and ziprasidone, have become available. Both drugs have shown adequate efficacy and tolerability in several double-blind trials of intramuscular administration in acutely agitated psychotic patients. Compared to conventional medication, injection forms of the new antipsychotics may have a faster onset of action and more favorable profile of adverse events. Alternative approaches to injection administration include liquid drug formula, orally disintegrating tablets and wafers, treatment initiation with high doses, or rapid dose escalation. Evidence suggests that second-generation antipsychotics should be among the first-line choices in the treatment of agitation in acute psychosis. R E V I E W A R T I C L E 1. Psychotic agitation Agitation is a transnosological syndrome; this cluster of pathological behavior occurs in a variety of psychiatric diseases including schizophrenia, bipolar disorder, or dementia. Agitation represents a poorly organized and aimless psychomotor activity stemming from physical or mental unease [1] Motor restlessness, increased responsiveness to external or internal stimuli, irritability, inappropriate and usually purposeless verbal and motor activity are the major hallmarks of the syndrome. It can readily result into a verbal or physical aggression toward objects or persons; the patients may then pose a danger to others [2, 3]. By definition, violence is a physical aggressive behavior that is intended to inflict harm to other people [4]. While acute aggressive behavior occurs as a state phenomenon, the tendency to engage in aggressive behavior over the lifetime is relatively stable since childhood [5]. Most frequently, victims of violent behavior are members of patient s family; the medical personnel or other patients are on the second place [6]. It should be also noted

2 Pavel Mohr, Ján Pečeňák, Jaromír Švestka, Dave Swingler & Tamás Treuer that often these are the first symptoms of mental illness that receive medical attention or lead to the psychiatric hospitalization. Not surprisingly, public opinion on psychiatry is significantly influenced by the aggressive or violent behavior of psychiatric patients; community tends to over-emphasize frequency of these incidents of violent crimes. Currently there are no specific guidelines on the management of aggressive behavior in psychotic patients. The aim of our paper is to review available pharmacological interventions with special focus on the new antipsychotics. Data from published controlled trials on the efficacy of the second generation antipsychotics were critically scrutinized. 2. Management of agitated patient Prediction of risk for violent behavior in psychotic patient can be a difficult task. A common accompanying factor that complicates psychotic agitation is concomitant abuse of alcohol and illicit drugs, which increases the risk of aggression [3]. Other risk factors include co-morbid personality disorders, unemployment, hyperactivity on in the clinical presentation and non-compliance with treatment; nevertheless, the best predictor of future violent behavior is a past history of violence [2, 7, 8, 9, 10]. Delusional ideas and/or commanding hallucinations may be associated with aggressive, often unpredictable behavior [2]. Although the first step should be a risk assessment, patients at the psychiatric interview are more frequently asked about violent thoughts and behavior directed to patient s themselves than about aggression to property or other persons [11]. Patient evaluation, if possible in an emergency setting, should precede any treatment initiation. Management of agitated/aggressive patient may be difficult and perilous as it is usually provided in emergency setting, often with insufficient data on patient s history and limited possibility for proper evaluation of basic psychiatric and physical condition. Timely management and targeted treatment intervention prevents Initial evaluation vital signs brief visual exam temporary diagnosis (delirium, psychosis, intoxication, etc.) Initial intervention talk to patient offer assistance Oral medication if needed and possible If not possible: Parenteral medication Restraints or seclusion if dangerous behavior persists escalation that may result in aggressive or violent behavior. The primary goal of interventions is to secure safety of the patient, staff, and other patients. The first step in the management of aggressive patients should be talking to a patient and offering help if needed. The next step is a decision to initiate oral drug treatment. In case of need, we may use assistance of other people in order to get sufficient power, outnumber agitated patient and secure physical control. If necessary, time-limited restraints or placement into seclusion may be used. Restraints should be used only when the patient poses an imminent danger to himself or others and when other less restrictive means failed [12]. Their use is temporary (2 4 hours); its application should be used to initiate treatment and to provide basic physical, instrumental and laboratory assessments. Patient in restraints usually calms down after a while [13]. Use of restraints or seclusion must be well documented, patient s mental and physical condition carefully monitored and all changes and progress of his status recorded. Seclusion or restraints are contraindicated in patients with severe physical conditions; also, drugs should be given to patients with head trauma. Although oral treatment is preferred, options in the pharmacotherapy of acute agitation include the parenteral (intramuscular [IM], intravenous [IV]) administration of the psychotropic drugs in order to facilitate onset of drug action and quickly alleviate symptoms. So-called rapid tranquilization is the repeated administration of medication over brief time intervals, usually within an hour or half-hour period. It was recommended previously to use very high doses of haloperidol, but later studies failed to support the administration of such extreme dosing. For example, Neborsky [14] compared mean doses of 48 mg vs mg/day of haloperidol and Donlon [15] compared three regimens of haloperidol dose escalation (from 20 mg or 100 mg at the 5 th day, 100 mg at the 10 th day and stable dose of haloperidol 10 mg). In both studies, significant differences between high a lower doses of haloperidol were not found. Treatment approaches must be comprehensive. Besides indispensable drug treatment, non-pharmacological, behavioral and environmental interventions for acute agitation are employed (Fig. 1). All objects near the patient that could be used as weapons (ashtrays, chairs, etc.) have to be removed, a safe passage to the secure area secured, and a sufficient number of the staff must be available. As the situation can be aggravated by overstimulation, it is helpful to screen the patient from others and turn off television and radio. We should never turn back to the agitated patient. Patients should be approached with confidence and spoken to in a soft, calm but authoritative tone. They should be allowed, asked questions designed to encourage them, to ventilate their needs. While eye contact is important, it should be broken if it makes the patient uncomfortable. The tone of the intervention is set in the first few minutes [2]. 328 Neuroendocrinology Letters No.4 August Vol.26, 2005 Copyright Neuroendocrinology Letters ISSN X

3 Treatment of acute agitation in psychotic disorders 3. Typical antipsychotics and benzodiazepines Pharmacological treatment is essential in control of psychotic agitation; parenteral drug administration is often needed (Table 1). Numerous factors, such as prior history and previous response to medication, play role in the choice of drug. In patients seen for the first time, somatic illness, trauma, and intoxication or withdrawal syndromes have to be ruled out [2]. Until recently, only of typical antidopaminergic antipsychotics in the form of injection were available (e.g., IM formulas of haloperidol, chlorpromazine, zuclopenthixol acetate, or levomepromazine). Dopamine D2 receptor antagonist tiapride has been used especially for the treatment of alcohol withdrawal, behavioral disturbances in the elderly and in organic mental disorders [16]. The advantages of the first generation antipsychotics include good antipsychotic efficacy, sedative effects in higher doses and several decades of experience with their administration. Their limitations are well-known adverse events including acute dystonia, extrapyramidal symptoms (EPS), akathisia, hypotension and painful injection with lower potency agents such as chlorpromazine and the risk of malignant neuroleptic syndrome. These adverse events are in contrast with the more favorable safety profiles of recently developed injection forms of second-generation antipsychotics. Benzodiazepines are used in treatment of psychotic agitation for their sedative and anxiolytic effects as monotherapy or in combination with antipsychotic drugs. They can augment efficacy of the latter and subsequently reduce the dose of an antipsychotic. A recent review of controlled trials reported combination of antipsychotics and benzodiazepines to be superior Advantages of typical antipsychotics (AP): proven antipsychotic efficacy sedative effect in higher dosage several decades of experience Limitations of typical antipsychotics: adverse events extrapyramidal symptoms, akathisia, (this is not a concern in acute IM treatment setting), hypotension, risk of malignant neuroleptic syndrome often pharmacokinetic not evaluated higher rate of non-compliance need for drug switch if second-generation AP are subsequently chosen for long-term therapy to the either agent alone in improvement rates and a lower incidence of EPS [17]. The most frequently prescribed are rapid acting (highly fat soluble) and/or high-potency agents such as lorazepam, clonazepam, or diazepam. The absorption of diazepam after intramuscular application is quite unpredictable, thus peroral administration is preferred. Lorazepam, the most widely used, is the only benzodiazepine that is reliably absorbed after IM administration and does not produce any active metabolite during elimination. Only a few randomized studies have found anti-aggressive effects of IM clonazepam [18], flunitrazepam [19], lorazepam [20], and midazolam [21, 22] comparable with those of haloperidol. Benzodiazepines play a crucial role in treatment of agitation during substance withdrawal syndromes. Table 1: Most common injection forms of psychotropic drugs Drug Dosage (mg) Half-time (hrs) Comments Lorazepam 0, Clonazepam Diazepam Can be used for treatment of alcohol withdrawal syndrome. No antipsychotic efficacy, risk of respiratory depression. Can be used for treatment of alcohol withdrawal syndrome. No antipsychotic efficacy, risk of respiratory depression. Can be used for treatment of alcohol withdrawal syndrome. Long half-time, slow absorption, active metabolites. Haloperidol 0, Risk of acute dystonia, EPS, akathisia, prolactin elevation, NMS. Chlorpromazine Risk of acute dystonia, EPS, akathisia, prolactin elevation, NMS. Levomepromazine Risk of acute dystonia, EPS, akathisia, prolactin elevation, NMS. Zuclopenthixol Risk of acute dystonia, EPS, akathisia, prolactin elevation, NMS. Olanzapine Risk of weight gain in long-term treatment (not in acute treatment). Low risk of EPS, does not induce prolongation of QTc interval. Ziprasidone Prolongation of QTc interval, low risk of EPS, does not induce weight gain. Legend: EPS = extrapyramidal syndrome; NMS = neuroleptic malignant syndrome Neuroendocrinology Letters No.4 August Vol.26, 2005 Copyright Neuroendocrinology Letters ISSN X 329

4 Pavel Mohr, Ján Pečeňák, Jaromír Švestka, Dave Swingler & Tamás Treuer The risks of respiratory depression, and dependency, tolerance and withdrawal in long-term administration, warrant caution. Benzodiazepines can augment sedative effects of other drugs and substances (alcohol), so they should not to be used in patients whose medical history is not known, with unknown type of intoxication or toxicological analysis. Although rare paradoxical reactions (hostility, violence) are unlikely to militate against use in acute clinical situations, a recent French review indicates that some benzodiazepines are associated with an increased risk of aggressive behavior in special patient populations [23]. 4. Second generation antipsychotics The second generation antipsychotics are generally effective and safe in the management of agitated behavior [review in: 17]. It should be noted that clozapine, the first agent of this group available for IM administration, is widely recognized as a very effective antiaggressive drug in the treatment of aggression and agitation in psychiatric patients, independent of psychiatric diagnosis [24, 25]. However, its use is limited due to the safety concerns regarding the risk of agranulocytosis. Recently, parenteral forms of two new antipsychotics have become available: ziprasidone and olanzapine; parenteral forms of other second generation antipsychotics (e.g., aripiprazole) are under development. Advantages of second-generation AP in acute treatment: i.m. formulation, rapid dissolving tablets, wafers, and solutions available for some of the atypicals rapid onset of action rather calming than sedating effects better tolerability and safety in comparison with typical AP (EPS) more information on pharmacokinetics and dosage regimen continuing treatment with the same drug during acute and maintenance treatment a. Olanzapine The efficacy of olanzapine injection form has been tested in two double-blind trials of schizophrenia [26, 27], in the treatment of acutely agitated patients with mania in bipolar disorder [28], and dementia of Alzheimer or vascular types [29] (Table 2). Most study subjects required a single injection to produce therapeutic effects. The time interval needed to reach maximum plasma concentrations (15 45 min after the IM application) indicates fast onset of action. In a pharmacokinetic study in healthy subjects, a 5 mg intramuscular dose of olanzapine for injection produced on average a maximum plasma concentration which is approximately 5 times higher than the maximum plasma concentration produced by a 5 mg oral dose (company data on file). The half-life observed after intramuscular administration is similar to that observed after oral dosing. The pharmacokinetics is linear across the clinical dosing range. After oral administration to healthy subjects, the mean terminal elimination half-life was 33 hours and the mean olanzapine plasma clearance was 26 L/hr. Olanzapine pharmacokinetics varied on the basis of smoking status, gender, and age. In a study of 201 patients with bipolar mania or mixed states [28], olanzapine injection (10 mg) was more effective than lorazepam (2 mg) and placebo after 2 hours in calming agitation. At the 24-hour study endpoint, olanzapine was still superior over placebo; lorazepam was not statistically different from both olanzapine and placebo. The three treatment arms showed no group difference in the frequency of adverse events. In the first of two schizophrenia studies [27], 270 patients were randomized into six treatment groups that were given, over a period of 24 hours, one to three injections of placebo or haloperidol (7.5 mg), or one of four dosages of olanzapine (2.5 mg; 5.0 mg; 7.5 mg; 10 mg). Efficacy was assessed two hours after the first injection and adverse events after 24 hours. All active treatments were significantly better than placebo; 2.5 mg of olanzapine was less effective than the higher olanzapine doses, and haloperidol. In olanzapine treatment cells, a trend indicating better efficacy with increasing doses was observed. Moreover, the doses of 5 mg, 7.5 mg, and 10 mg showed faster onset of action: they were statistically superior to placebo already 30 minutes after administration. The most frequent adverse event was hypotension in olanzapine treated patients (seven patients, none on haloperidol or placebo). Two haloperidol treated patients developed acute dystonia, one patient on olanzapine and six on haloperidol developed treatment-emergent Parkinsonism and akathisia was observed in two olanzapine patients and three haloperidol subjects. Concomitant anticholinergic medication had to be prescribed for three haloperidol and one olanzapine treated patients. In the second study [26], 321 patients were randomly assign to olanzapine (N=131), haloperidol (N=126), or placebo (N=54); 285 patients (91.6%) completed the study. IM olanzapine patients were administered one to three IM injections of olanzapine (10 mg) over a period of 24 hours. Evaluation at the a-priori set time points showed that olanzapine and haloperidol reduced agitation significantly better than placebo. Moreover, at assessments after 15, 30, and 45 minutes, patients receiving olanzapine displayed significantly greater improvement on the PANSS EC compared to haloperidol-treated patients, again suggesting faster onset of action. Olanzapine was also better tolerated: EPS were observed in 0.8% olanzapine treated patients compared to 5.6% patients on haloperidol. In the haloperidol group, there was a 7% incidence of acute dystonia (none in the olanzapine group). Anticholinergic medication 330 Neuroendocrinology Letters No.4 August Vol.26, 2005 Copyright Neuroendocrinology Letters ISSN X

OVERVIEW The term Lewy body dementias (LBD) represents two clinical entities dementia with Lewy bodies (DLB) and Parkinson s disease dementia (PDD). While the temporal sequence of symptoms is different

Family Guide To Understanding Antipsychotic Medications Prescribed For Persons With Mental Retardation and Developmental Disabilities What are Psychotic Symptoms? Antipsychotic medications are powerful,

The pharmacological management of aggression in the nursing home requires careful assessment and methodical treatment to assure maximum safety for patients, nursing home residents and staff. Aggressive

GUIDELINES GUIDELINES FOR USE OF PSYCHOTHERAPEUTIC MEDICATIONS IN OLDER ADULTS Preamble The American Society of Consultant Pharmacists has developed these guidelines for use of psychotherapeutic medications

Bipolar disorder Bipolar (manic-depressive illness) is a recurrent mode disorder. The patient may feel stable at baseline level but experience recurrent shifts to an emotional high (mania or hypomania)

SUPPLEMENT 1: (Supplementary Material for online publication) Antipsychotic drug prescription for patients with dementia in long-term care. A practice guideline for physicians and caregivers About this

TREATMENT GUIDELINES Psychopharmacotherapy for Children and Adolescents Guideline 7 Psychopharmacotherapy for Children and Adolescents Description There are few controlled trials to guide practitioners

Antipsychotic drugs Antipsychotics can be broadly classified into first generation antipsychotics (FGAs, formerly known as typical antipsychotics) and second generation antipsychotics (SGAs, formerly known

Pharmacological Management of Prodromal and First Episode Schizophrenia The optimal time to treat schizophrenia is as early in the course and as close to the onset as possible. Often the onset of the illness

This is a new guideline. These guidelines are intended to support General Practitioners in the care of their patients with dementia both in the community and in care homes. It incorporates NICE clinical

This continuing education activity is co-sponsored by Indiana University School of Medicine and by CME Outfitters, LLC. Indiana University School of Medicine and CME Outfitters, LLC, gratefully acknowledge

These Guidelines are based in part on the following: American Academy of Child and Adolescent Psychiatry s Practice Parameter for the Assessment and Treatment of Children and Adolescents With Bipolar Disorder,

Depression is a common biological brain disorder and occurs in 7-12% of all individuals over the age of 65. Specific groups have a much higher rate of depression including the seriously medically ill (20-40%),

F-329 Excerpt from TABLE I MEDICATION ISSUES OF PARTICULAR RELEVANCE - Antipsychotic Medications This table lists alphabetically, examples of some categories of medications that have the potential to cause

ASSESSMENT AND MANAGEMENT OF PSYCHOSIS IN PERSONS WITH DEMENTIA Overview: Psychosis is a common clinical feature of dementia. Hallucinations and delusions are the two most common types of psychotic symptoms

Faculty of the Psychiatry of Old Age Atypical antipsychotics and BPSD Prescribing update for Old Age Psychiatrists A) Introduction 1. In March 2004 the Faculty for the Psychiatry of Old Age of the Royal

Update on Treatment of the Dementias Mark Pippenger, MD Behavioral Neurology Associate Clinical Professor of Neurology University of Arkansas for Medical Sciences Disclosures I will be discussing off-label

The atypical antipsychotics are a class of drugs that are used to treat a number of behavioral health disorders, including schizophrenia, other psychotic disorders, mood disorders, and behavioral agitation

for schizophrenia (oh-lan-zah-peen) Summary Olanzapine as pamoate monohydrate is a long-acting injectable or depot form of olanzapine and provides another option for maintenance treatment of schizophrenia.

Dementa Formulary Guidance [v1.0] 1. Introduction These Guidelines are intended for routine use. However there will be instances where they are not suitable for the patient you are managing, where more

1 of 8 USE OF CHOLINESTERASE (AChE) INHIBITORS The cholinesterase inhibitor anti-dementia drugs are indicated for the symptomatic treatment of patients with mild to moderate dementia of the Alzheimer s

Bipolar Disorder What is bipolar disorder? Bipolar disorder, or manic depression, is a medical illness that causes extreme shifts in mood, energy, and functioning. These changes may be subtle or dramatic

Some critics of Janssen, including plaintiff s lawyers, have stated it is improper for Risperdal to have been used to treat elderly dementia patients. As you consider that position, we suggest you consider

Antipsychotic Medications and the Risk of Diabetes and Cardiovascular Disease Professional Tool #1: Screening and Monitoring in a High-Risk Population: Questions and Answers Overview of Cardiometabolic

updated 2012 Treatment of alcohol withdrawal delirium Q3: In the treatment of alcohol withdrawal delirium, are benzodiazepines or antipsychotics safe and effective when compared to a placebo/appropriate

Use of Psychotropics in Long-term Care Facilities for the Elderly Psychotropic medications are frequently prescribed in long-term care facilities for the elderly, despite the fact that a number of factors

1 DEPRESSION CARE PROCESS STEP EXPECTATIONS RATIONALE ASSESSMENT/PROBLEM RECOGNITION 1. Did the staff and physician seek and document risk factors for depression and any history of depression? 2. Did staff

BIPOLAR DISORDER A GUIDE FOR INDIVIDUALS AND FAMILIES FOR THE TREATMENT OF BIPOLAR DISORDER IN ADULTS A publication of the Massachusetts Department of Mental Health and the Massachusetts Division of Medical

COMPREHENSIVE MANAGEMENT OF THE ELDERLY PATIENT WITH MANIA Manic depressive illness is a biological brain disorder that produces significant alterations of mood and psychosis. Mania in the elderly occurs

Update on guidelines on biological treatment of depressive disorder Dr. Henry CHEUNG Psychiatrist in private practice 2013 update International Task Force of World Federation of Societies of Biological

The Agitated Patient in the Emergency Department On day 1 this 22 yo male is brought to ED for strange and unruly behavior at home. His mother had brought him in because he had not slept for the past 4

Pain Medication Taper Regimen Time frame to taper off 30-60 days Medication to taper Taper Regimen Comments Methadone Taper by no more than 25% Morphine Taper by no more than 25% Tramadol Taper by no more

MENTAL HEALTH EMERGENCIES/CLINICAL POLICY Clinical Policy: Critical Issues in the Diagnosis and Management of the Adult Psychiatric Patient in the Emergency Department From the American College of Emergency

Clozapine Management Program Description Magellan of Arizona Pharmacy Program Background: Magellan Health Services of Arizona recognizes the importance of a clozapine program. Clozapine received increased

NEW ZEALAND HEALTH TECHNOLOGY ASSESSMENT (NZHTA) THE CLEARING HOUSE FOR HEALTH OUTCOMES AND HEALTH TECHNOLOGY ASSESSMENT Department of Public Health and General Practice Christchurch School of Medicine,

The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use London, 26 April 2001 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON CLINICAL

Dr IM Joubert Alcohol and nicotine are widely abused substances and are often used together One study showed that 15% of patients visiting a primary care practice for any reason had either an at-risk pattern

Bipolar disorder F Colin 1. Introduction Bipolar disorder (BD) presents in different phases over time and is often complicated by comorbid conditions such as substance-use disorders and anxiety disorders.

Case 48 year old man admitted complaining of hallucinations. Mild hallucinations for a year. Worsened tremor for 3 weeks and then markedly worse hallucinations last 2 days History of psoriatic arthritis,

Treatments for Major Depression Drug Treatments The two (2) classes of drugs that are typical antidepressants are: 1. 2. These 2 classes of drugs increase the amount of monoamine neurotransmitters through

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ABILIFY safely and effectively. See full prescribing information for ABILIFY. ABILIFY (aripiprazole)

The Clinical Level of Care Guidelines contained on the following pages have been developed as a guide to assist care managers, physicians and providers in making medical necessity decisions about the least

PSYCHOPHARMACOLOGY AND WORKING WITH PSYCHIATRY PROVIDERS Juanaelena Garcia, MD Psychiatry Director Institute for Family Health Learning Objectives Learn basics about the various types of medications that

EMA/303592/2015 Summary of the risk management plan (RMP) for Aripiprazole Pharmathen (aripiprazole) This is a summary of the risk management plan (RMP) for Aripiprazole Pharmathen, which details the measures

Depression is a biological brain disorder that is common in nursing home residents and occurs in 7-12% of all individuals over the age of 65. Specific groups have a much higher rate of depression including

Issue date: July 2006 Bipolar disorder The management of bipolar disorder in adults, children and adolescents, in primary and secondary care NICE clinical guideline 38 Developed by the National Collaborating

Medications for bipolar disorder Findings from Australian National Survey of Mental Health and Wellbeing (Mitchell et al, 2004) In 12 months, only one-third saw a mental health professional 40% received

Clinical Potential of Minocycline for Depression with Psychotic Features Tsuyoshi Miyaoka Department of Psychiatry Shimane University School of Medicine Minocycline 1. Second-generation tetracycline which

The following medication chart is provided as a brief guide to some of the medications used in the management of various behavior disorders, along with their potential benefits and possible side effects.

INTRODUCTION A BRIEF OVERVIEW OF PSYCHOTROPIC MEDICATION USE FOR PERSONS WITH INTELLECTUAL DISABILITIES Individuals with intellectual disabilities are not uncommonly prescribed psychotropic medications.

www.bpac.org.nz keyword: dementia Antipsychotics in people with dementia an update and reminder Key concepts: Non-pharmacological treatments for the behavioural and psychological symptoms of dementia (BPSD)

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ABILIFY safely and effectively. See full prescribing information for ABILIFY ABILIFY (aripiprazole)

Formulary for mental health medications The Medicines Management Committee has approved this list of formulary medicines with links to national and local prescribing guidelines. If a medicine for a mental

Alcohol Withdrawal Syndromes Should You Treat This Patient s Alcohol Withdrawal With Benzodiazepines?! Meta-analysis of RCTs of benzodiazepines for the treatment of alcohol withdrawal! 11 RCTs identified,